Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Drugs
Erschienen in: Drugs 8/2013

01.06.2013 | Therapy in Practice

Treatment of Acne Vulgaris During Pregnancy and Lactation

verfasst von: Y. L. Kong, H. L. Tey

Erschienen in: Drugs | Ausgabe 8/2013

Einloggen, um Zugang zu erhalten

Abstract

Acne vulgaris is a common problem encountered by pregnant and lactating women. Unfortunately, in clinical practice, treatment is often not optimized as a result of the lack of safety data and unified recommendations on the use of the various anti-acne therapies. In this narrative review, current data on their safety is summarized. We recommend the use of topical medications as first-line treatment for acne vulgaris in pregnant and lactating women. These include antibiotics (erythromycin, clindamycin, metronidazole and dapsone), benzoyl peroxide, azelaic acid and salicylic acid. Oral agents and/or light-based therapy may be considered as second-line treatment. The former consists of oral macrolides (erythromycin and azithromycin), cephalexin or zinc compounds. Blue–violet or red light phototherapy may be used as monotherapy or in addition to topical and/or oral therapies. Hormonal therapy, antibiotics consisting of tetracyclines, co-trimoxazole and fluoroquinolones, and both oral and topical retinoids should be avoided.
Literatur
1.
Kamangar F, Shinkai K. Acne in the adult female patient: a practical approach. Int J Dermatol. 2012;51(10):1162–74.PubMedCrossRef
2.
Mays RM, Gordon RA, Wilson JM, et al. New antibiotic therapies for acne and rosacea. Dermatol Ther. 2012;25(1):23–37.PubMedCrossRef
3.
Feneran AN, Kaufman WS, Dabade TS, et al. Retinoid plus antimicrobial combination treatments for acne. Clin Cosmet Investig Dermatol. 2011;4:79–92.PubMed
4.
Bozzo P, Chua-Gocheco A, Einarson A. Safety of skin care products during pregnancy. Can Fam Phys. 2011;57(6):665–7.
5.
Fried RG, Wechsler A. Psychological problems in the acne patient. Dermatol Ther. 2006;19(4):237–40.PubMedCrossRef
6.
Wong JW, Heller MM, Murase JE. Caution advised in interpretation of US FDA risk classification for dermatological medications during pregnancy. Dermatol Online J. 2012;18(10):15.PubMed
7.
Hale T. Medications and mothers’ milk. 14th ed. Amarillo: Hale Publishing; 2010.
8.
American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108:776.
9.
10.
Hale EK, Pomeranz MK. Dermatologic agents during pregnancy and lactation: an update and clinical review. Int J Dermatol. 2002;41(4):197–203.PubMedCrossRef
11.
Rozex [package insert]. Watford: Galderma; 2012.
12.
ACZONE (dapsone) gel [package insert]. Irvine: Allergan, Inc.; 2013.
13.
Tuffanelli DL. Successful pregnancy in a patient with dermatitis herpetiformis treated with low dose dapsone. Arch Dermatol. 1982;118(11):876.PubMedCrossRef
14.
Sanders SW, Zone JJ, Foltz RL, et al. Hemolytic anemia induced by dapsone transmitted through breast milk. Ann Intern Med. 1982;96(4):465–6.PubMedCrossRef
15.
Webster GF. Is topical dapsone safe in glucose-6-phosphate dehydrogenase-deficient and sulfonamide-allergic patients? J Drugs Dermatol. 2010;9(5):532–6.PubMed
16.
Jung JY, Kwon HH, Yeom KB, et al. Clinical and histological evaluation of 1% nadifloxacin cream in the treatment of acne vulgaris in Korean patients. Int J Dermatol. 2011;50(3):350–7.PubMedCrossRef
17.
Selcen D, Seidman S, Nigro MA. Otocerebral anomalies associated with topical tretinoin use. Brain Dev. 2000;22(4):218–20.PubMedCrossRef
18.
Autret E, Berjot M, Jonville-Béra AP, et al. Anophthalmia and agenesis of optic chiasma associated with adapalene gel in early pregnancy. Lancet. 1997;350(9074):339.PubMedCrossRef
19.
Loureiro KD, Kao KK, Jones KL, et al. Minor malformations characteristic of the retinoic acid embryopathy and other birth outcomes in children of women exposed to topical tretinoin during early pregnancy. Am J Med Genet A. 2005;136(2):117–21.PubMed
20.
Panchaud A, Csajka C, Merlob P, et al. Pregnancy outcome following exposure to topical retinoids: a multicentre prospective study. J Clin Pharmacol. 2012;52(12):1844–51.PubMedCrossRef
21.
Leachman SA, Reed BR. The use of dermatologic drugs in pregnancy and lactation. Dermatol Clin. 2006;24:167–97.PubMedCrossRef
22.
Akhavan A, Bershad S. Topical acne drugs: review of clinical properties, systemic exposure, and safety. Am J Clin Dermatol. 2003;4:473–92.PubMedCrossRef
23.
Trivedi NA. A meta-analysis of low-dose aspirin for prevention of preeclampsia. J Postgrad Med. 2011;57(2):91–5.PubMedCrossRef
24.
The WHO Working Group, Bennet PN (ed). Drugs and human lactation. Oxford: Elsevier; 1988. p. 325–6.
25.
Källén BA, Otterblad Olausson P, Danielsson BR. Is erythromycin therapy teratogenic in humans? Reprod Toxicol. 2005;20(2):209–14.PubMedCrossRef
26.
McCormack WM, George H, Donner A, et al. Hepatotoxicity of erythromycin estolate during pregnancy. Antimicrob Agents Chemother. 1977;12(5):630–5.PubMedCrossRef
27.
Hayashi N, Kawashima M. Efficacy of oral antibiotics on acne vulgaris and their effects on quality of life: a multicenter randomized controlled trial using minocycline, roxithromycin and faropenem. J Dermatol. 2011;38(2):111–9.PubMedCrossRef
28.
Czeizel AE, Rockenbauer M, Olsen J, et al. A case–control teratological study of spiramycin, roxithromycin, oleandomycin and josamycin. Acta Obstet Gynecol Scand. 2000;79(3):234–7.PubMedCrossRef
29.
Sorensen HT, Skriver MV, Pedersen L, et al. Risk of infantile hypertrophic pyloric stenosis after maternal postnatal use of macrolides. Scand J Infect Dis. 2003;35:104–6.PubMedCrossRef
30.
Harmon T, Burkhart G, Applebaum H. Transfer of probenecid and cephalexin into breast milk. Ann Pharmacother. 2006;40(5):986–9.CrossRef
31.
Fenner JA, Wiss K, Levin NA. Oral cephalexin for acne vulgaris: clinical experience with 93 patients. Pediatr Dermatol. 2008;25(2):179–83.PubMedCrossRef
32.
Rothman KF, Pochi PE. Use of oral and topical agents for acne in pregnancy. J Am Acad Dermatol. 1988;19(3):431–42.PubMedCrossRef
33.
Wenk RE, Gebhardt FC, Bhagavan BS, et al. Tetracycline-associated fatty liver of pregnancy, including possible pregnancy risk after chronic dermatologic use of tetracycline. J Reprod Med. 1981;26(3):135–41.PubMed
34.
Spencer JP, Gonzalez LS 3rd, Barnhart DJ. Medications in the breast-feeding mother. Am Fam Phys. 2001;64(1):119–26.
35.
Ho JM, Juurlink DN. Considerations when prescribing trimethoprim-sulfamethoxazole. CMAJ. 2011;183(16):1851–8.PubMed
36.
Katsambas A, Dessinioti C. New and emerging treatments in dermatology: acne. Dermatol Ther. 2008;21(2):86–95 (Review).
37.
Briggs GG, Freeman RK, Yaffe SJ, eds. Drugs in pregnancy and lactation. 5th ed. Baltimore: Williams & Wilkins; 1998.
38.
Harmon T, Burkhart G, Applebaum H. Perforated pseudomembranous colitis in the breast-fed infant. Pediatr Surg. 1992;27(6):744–6.CrossRef
39.
Dréno B, Blouin E. Acne, pregnant women and zinc salts: a literature review. Ann Dermatol Venereol. 2008;135(1):27–33.PubMedCrossRef
40.
Martínez-Frías ML, Bermejo E, Rodríguez-Pinilla E, et al. Periconceptional exposure to contraceptive pills and risk for Down syndrome. J Perinatol. 2001;21(5):288–92.PubMedCrossRef
41.
Tankeyoon M, Dusitain N, Chalapati S, et al. Effects of hormonal contraceptives on milk volume and infant growth. WHO Special Programme of Research, Development and Research Training in Human Reproduction. Task force on oral contraceptives. Contraception. 1984;30:505–22.PubMedCrossRef
42.
Maloney ME, Stone SP. Isotretinoin and iPledge: a view of results. J Am Acad Dermatol. 2011;65(2):418–9.PubMedCrossRef
43.
44.
McDonagh AF, Lightner DA. ‘Like a shrivelled blood orange’—bilirubin, jaundice, and phototherapy. Pediatrics. 1985;75(3):443–55.PubMed
45.
Yang YG, Zou XB, Zhao H, et al. Photodynamic therapy of condyloma acuminata in pregnant women. Chin Med J (Engl). 2012;125(16):2925–8.
46.
Lehmann HP, Robinson KA, Andrews JS, et al. Acne therapy: a methodological review. J Am Acad Dermatol. 2002;47:231–40.PubMedCrossRef
47.
Archer CB, Cohen SN, Baron SE. Guidance on the diagnosis and clinical management of acne. Clin Exp Dermatol. 2012;37(Suppl 1):1–6.PubMedCrossRef
48.
Strauss JS, Krowchuk DP, Leyden JJ, et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol. 2007;56(4):651–63.PubMedCrossRef
49.
Graupe K, Cunliffe WJ, Gollnick HP, et al. Efficacy and safety of topical azelaic acid (20 percent cream): an overview of results from European clinical trials and experimental reports. Cutis. 1996;57(1 Suppl):20–35.PubMed
50.
Dreno B, Moyse D, Alirezai M, et al. Multicenter randomized comparative double-blind controlled clinical trial of the safety and efficacy of zinc gluconate versus minocycline hydrochloride in the treatment of inflammatory acne vulgaris. Dermatology. 2001;203(2):135–40.PubMedCrossRef
Metadaten
Titel
Treatment of Acne Vulgaris During Pregnancy and Lactation
verfasst von
Y. L. Kong
H. L. Tey
Publikationsdatum
01.06.2013
Verlag
Springer International Publishing AG
Erschienen in
Drugs / Ausgabe 8/2013
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-013-0060-0

Weitere Artikel der Ausgabe 8/2013

Drugs 8/2013 Zur Ausgabe

Adis Drug Evaluation

S-1 (Teysuno®): A Review of Its Use in Advanced Gastric Cancer in Non-Asian Populations

Review Article

Drug-Induced Macular Edema

Leading Article

Combination Molecularly Targeted Drug Therapy in Metastatic Melanoma: Progress to Date

Adis Drug Evaluation

Tofacitinib: A Review of its Use in Adult Patients with Rheumatoid Arthritis

Adis Drug Evaluation

Apixaban: A Review of its Use for Reducing the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation

Systematic Review

Sequential Therapy Versus Standard Triple-Drug Therapy for Helicobacter pylori Eradication: a Systematic Review of Recent Evidence